A carregar...
HER2 therapy: Molecular mechanisms of trastuzumab resistance
Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor. The majority of patients with metastatic breast cancer who initially respond to trastuzumab develop resistance within one year of treatment initiation, and in the adjuvant setting 15% of patients still relapse d...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2006
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1797036/ https://ncbi.nlm.nih.gov/pubmed/17096862 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr1612 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|